Belite Bio, Inc
BLTE
株式のランク
#3051
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
株価
$148.24
最終同期: 2026-10-19
時価総額
$5.97B
変化（1日）
3.82%
変化（1年）
64.04%
国
US
取引 Belite Bio, Inc (BLTE)
カテゴリー
Healthcare
Belite Bio, Inc（BLTE）の利益
Jun 2026 時点の利益 TTM: $-102.31M
Belite Bio, Inc の最新の財務報告によると、同社の現在の利益は $-102.31M です。2023 年には $-31.62M の利益を上げ、これは 2022 年の利益 $-12.65M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Belite Bio, Inc の利益の推移（2020 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-102.31M | 183.11% |
| 2024 | $-36.14M | 14.28% |
| 2023 | $-31.62M | 150.02% |
| 2022 | $-12.65M | 30.85% |
| 2021 | $-9.67M | 68.05% |
| 2020 | $-5.75M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | -5,255.85% |
US
|
|
| $-3.09B | 2,917.33% |
US
|
|
| $-4.02B | 3,825.56% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -2,006.63% |
NL
|
